| 
| ||||||||||||||||||
- Description
- Disease & phenotype
- Genes & alleles
- Genotyping
- Health & care
- References
- Pricing & purchasing
- Terms of use
Description
The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.
Strain Information
Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Background Strain BALB/c Donor Strain (C57BL/6 x SJL)F2 H2 Haplotype d Generation N10F?+N1p (18-DEC-05)
Generation DefinitionsDonating Investigator Linda Sherman, The Scripps Research Institute Appearance
pink-eye, albino
Related Genotype: A/? Tyrc/TyrcDescription
Transgenic mice are viable, fertile, normal in size, normoglycemic and do not display any gross physical or behavioral abnormalities. Immunohistochemistry reveals pancreatic islet cell expression of the transgene and no expression in the spleen, kidney or thymus. Isolated islets stain normally for insulin and are morphologically indistinguishable from control islets. Additional functional studies found no expression in bone marrow. Histology revealed no insulitis and the single transgenic mice do not become diabetic. T-cell proliferation assays, Cytotoxic Lymphocyte (CTL) assays, and adoptive transfer studies performed using transgenic mice indicate significantly reduced class 1 and class II T-cell responses compared to controls. Hemagglutination inhibition assays of sera from HA primed transgenic mice indicate antibody titers slightly lower but nearly equivalent to HA primed control mice. Antibody titers of all transgenic mice tested were significantly higher than preimmune levels. When mated with Tg(TcraCl4,TcrbCl4) mice, the double transgenic neonates become spontaneously diabetic after birth and die within 10 days.This is a good model for studying peripheral tolerance.
Development
C.Cg-Tg(Ins2-HA)165Bri/ShrmJ expresses influenza hemagglutinin (HA) molecule from the well characterized influenza A/PR/8/34 under the control of the rat insulin 2 promoter (Ins2). This transgene was injected into (C57BL/6J x SJL)F2 oocytes. Resulting progeny from founder line 2917-5 was backcrossed to H2d strains BALB/cBy for 10 generations and B10.D2 for 10 generations or NOD/Shi, H2g7, for 13 generations prior to intercrossing. In 2005, the Jackson Laboratory received C.Cg-Tg(Ins2-HA)165Bri/ShrmJ at generation N10F20.
Control Information
| Control | ||
|---|---|---|
| 001026 BALB/cByJ | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying Tg(Ins2-HA)165Bri allele
005534 B10.Cg-H2d Tg(Ins2-HA)165Bri/ShrmJ 005685 NOD.Cg-Tg(Ins2-HA)165Bri/ShrmJ View Strains carrying Tg(Ins2-HA)165Bri (2 strains)
012278 STOCK Tg(Piwil1)1Ghan/J 012275 STOCK Tg(Piwil2)1Ghan/J 012280 STOCK Tg(Piwil4)1Ghan/J
Phenotype
Phenotype Information
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Tg(Ins2-HA)165Bri/0
B10.Cg- H2d Tg(Ins2-HA)165Bri/ShrmJ
- immune system phenotype
- *normal* immune system phenotype
- mice exhibit no evidence of autoimmunity (MGI Ref ID J:86430)
- abnormal CD4-positive T cell physiology
- decreased T cell proliferation
- following priming with HA peptides (MGI Ref ID J:86430)
- endocrine/exocrine gland phenotype
- *normal* endocrine/exocrine gland phenotype
- islet beta cells exhibit normal morphology (MGI Ref ID J:86430)
- hematopoietic system phenotype
- decreased T cell proliferation
- following priming with HA peptides (MGI Ref ID J:86430)
- cellular phenotype
- decreased T cell proliferation
- following priming with HA peptides (MGI Ref ID J:86430)
This mouse can be used to support research in many areas including:
Immunology, Inflammation and Autoimmunity Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Rearranged Antigen-Specific T Cell Receptor Transgenes
T Cell Receptor Signaling Defects
Research Tools
Cancer Research
specific T cell deficiency
tumor immunology
Diabetes and Obesity Research
Immunology and Inflammation Research
T Cell Receptor Transgenics
Genes & Alleles
Gene & Allele Information provided by MGI
| Allele Symbol | Tg(Ins2-HA)165Bri | ||
|---|---|---|---|
| Allele Name | transgene insertion 165, Ralph Brinster | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | 2917-5; Ins-HA; InsHA; RIP-HA; Tg(Ins-2,HA)Bri165; | ||
| Mutation Made By | Dr. Ralph Brinster, University of Pennsylvania | ||
| Expressed Gene | HA, influenza hemagglutinin, | ||
| Promoter | Ins2, insulin 2, rat | ||
| Molecular Note | The transgenic construct consisted of the rat insulin 2 promoter fused to sequence encoding influenza hemagglutinin (HA) followed by the 3' untranslated region and polyadenylation signal from the H2-Ea. HA was from influenza A/PR/8/34. This rat insulin 2 promoter is active in pancreatic beta-cells. [MGI Ref ID J:86430] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(Ins2-HA)165Bri, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References provided by MGI
Selected Reference(s)
Lo D; Freedman J; Hesse S; Palmiter RD; Brinster RL; Sherman LA. 1992. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur J Immunol 22(4):1013-22. [PubMed: 1348026] [MGI Ref ID J:86430]
Additional References
Tg(Ins2-HA)165Bri relatedApostolou I; Hao Z; Rajewsky K; von Boehmer H. 2003. Effective destruction of Fas-deficient insulin-producing beta cells in type 1 diabetes. J Exp Med 198(7):1103-6. [PubMed: 14530378] [MGI Ref ID J:85985]
Bercovici N; Heurtier A; Vizler C; Pardigon N; Cambouris C; Desreumaux P; Liblau R. 2000. Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. J Immunol 165(1):202-10. [PubMed: 10861053] [MGI Ref ID J:62874]
Guo Z; Dose M; Kovalovsky D; Chang R; O'Neil J; Look AT; von Boehmer H; Khazaie K; Gounari F. 2007. Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood 109(12):5463-72. [PubMed: 17317856] [MGI Ref ID J:145430]
Hernandez J; Aung S; Redmond WL; Sherman LA. 2001. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med 194(6):707-17. [PubMed: 11560988] [MGI Ref ID J:100011]
Hill M; Deghmane AE; Segovia M; Zarantonelli ML; Tilly G; Blancou P; Beriou G; Josien R; Anegon I; Hong E; Ruckly C; Antignac A; Ghachi ME; Boneca IG; Taha MK; Cuturi MC. 2011. Penicillin Binding Proteins as Danger Signals: Meningococcal Penicillin Binding Protein 2 Activates Dendritic Cells through Toll-Like Receptor 4. PLoS One 6(10):e23995. [PubMed: 22046231] [MGI Ref ID J:178081]
Kreuwel HT; Biggs JA; Pilip IM; Pamer EG; Lo D; Sherman LA. 2001. Defective CD8+ T cell peripheral tolerance in nonobese diabetic mice. J Immunol 167(2):1112-7. [PubMed: 11441123] [MGI Ref ID J:107321]
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA. 1999. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol 163(8):4335-41. [PubMed: 10510373] [MGI Ref ID J:100013]
Lyman MA; Aung S; Biggs JA; Sherman LA. 2004. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol 172(11):6558-67. [PubMed: 15153470] [MGI Ref ID J:90532]
Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA. 2005. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 174(5):2563-72. [PubMed: 15728462] [MGI Ref ID J:97745]
Martinez X; Kreuwel HT; Redmond WL; Trenney R; Hunter K; Rosen H; Sarvetnick N; Wicker LS; Sherman LA. 2005. CD8+ T Cell Tolerance in Nonobese Diabetic Mice Is Restored by Insulin-Dependent Diabetes Resistance Alleles. J Immunol 175(3):1677-85. [PubMed: 16034108] [MGI Ref ID J:100008]
Morgan DJ; Kreuwel HT; Fleck S; Levitsky HI; Pardoll DM; Sherman LA. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160(2):643-51. [PubMed: 9551898] [MGI Ref ID J:45169]
Morgan DJ; Kurts C; Kreuwel HT; Holst KL; Heath WR; Sherman LA. 1999. Ontogeny of T cell tolerance to peripherally expressed antigens. Proc Natl Acad Sci U S A 96(7):3854-8. [PubMed: 10097127] [MGI Ref ID J:109899]
Morgan DJ; Liblau R; Scott B; Fleck S; McDevitt HO; Sarvetnick N; Lo D; Sherman LA. 1996. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol 157(3):978-83. [PubMed: 8757600] [MGI Ref ID J:99756]
Morgan DJ; Nugent CT; Raveney BJ; Sherman LA. 2004. In a transgenic model of spontaneous autoimmune diabetes, expression of a protective class II MHC molecule results in thymic deletion of diabetogenic CD8+ T cells. J Immunol 172(2):1000-8. [PubMed: 14707073] [MGI Ref ID J:100010]
Pauza ME; Nguyen A; Wolfe T; Ho IC; Glimcher LH; von Herrath M; Lo D. 2001. Variable effects of transgenic c-Maf on autoimmune diabetes. Diabetes 50(1):39-46. [PubMed: 11147792] [MGI Ref ID J:133138]
Redmond WL; Marincek BC; Sherman LA. 2005. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol 174(4):2046-53. [PubMed: 15699134] [MGI Ref ID J:100009]
Redmond WL; Wei CH; Kreuwel HT; Sherman LA. 2008. The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen. J Immunol 180(8):5275-82. [PubMed: 18390708] [MGI Ref ID J:134242]
Saxena A; Desbois S; Carrie N; Lawand M; Mars LT; Liblau RS. 2012. Tc17 CD8+ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model. J Immunol 189(6):3140-9. [PubMed: 22904307] [MGI Ref ID J:189912]
Shanker A; Brooks AD; Jacobsen KM; Wine JW; Wiltrout RH; Yagita H; Sayers TJ. 2009. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res 69(16):6615-23. [PubMed: 19654302] [MGI Ref ID J:151764]
Smith SS; Patterson T; Pauza ME. 2005. Transgenic Ly-49A inhibits antigen-driven T cell activation and delays diabetes. J Immunol 174(7):3897-905. [PubMed: 15778344] [MGI Ref ID J:97982]
VanOosten RL; Griffith TS. 2007. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res 67(24):11980-90. [PubMed: 18089829] [MGI Ref ID J:129272]
Yi Z; Li L; Garland A; He Q; Wang H; Katz JD; Tisch R; Wang B. 2012. IFN-gamma receptor deficiency prevents diabetes induction by diabetogenic CD4+, but not CD8+, T cells. Eur J Immunol 42(8):2010-8. [PubMed: 22865049] [MGI Ref ID J:187880]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.Colony Maintenance
Diet Information LabDiet® 5K52/5K67
Pricing and Purchasing
Pricing, Supply Level & Notes, Controls
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2250.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2925.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
|
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
General Supply Notes
- This strain is included in the Type 1 Diabetes Repository collection.
- Genomic DNA is available for this strain from the Mouse DNA Resource.
Control Information
| Control | ||
|---|---|---|
| 001026 BALB/cByJ | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries regarding Terms of UseContracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.